中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 2
Feb.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(2): 279-283

Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2016.02.016

  • Department of Infectious Diseases,Tongcheng People's Hospital

  • Received Date: 2015-06-05
  • Published Date: 2016-02-20
    Abstract
  • Objective To investigate the effects of nucleos( t) ide analogues( NAs) on the estimated glomerular filtration rate( e GFR) and serum creatinine( Scr) in patients with chronic hepatitis B( CHB). Methods A total of 184 patients with CHB who visited and were hospitalized in the Second Affiliated Hospital of Dalian Medical University from September 2010 to September 2014 were enrolled and divided into adefovir( ADV) group( 58 patients),telbivudine( LDT) group( 62 patients),and entecavir( ETV) group( 64 patients),according to the NAs administered. The course of treatment was 104 weeks for all groups. The changes in e GFR and Scr level in each group after treatment were evaluated. The chi- square test was applied for comparison of categorical data between groups; the Wilcoxon rank sum test was applied for comparison of continuous data before and after treatment within one group,and Kruskal- Wallis H rank sum test was applied for comparison between groups. Results In the ETV group,there were no significant changes in Scr and e GFR after 52 and 104 weeks of treatment( all P > 0. 05); in the ADV group,there was a significant increase in Scr level and a significant reduction in e GFR after 52 and 104 weeks of treatment( Z =- 3. 020,- 3. 456,- 4. 623,and- 4. 831,P = 0. 018,0. 008,0. 004,and < 0. 001,respectively); in the LDT group,there was a significant reduction in Scr level and a significant increase in e GFR after 52 and 104 weeks of treatment( Z =-5. 596,- 5. 687,- 5. 335,and- 5. 162,P = 0. 007,0. 003,0. 002,and < 0. 001,respectively). After 104 weeks of treatment,the distribution of e GFR showed a significant difference between the ADV group and the LDT group( χ2= 21. 039,P < 0. 001); in the LDT group,77. 78%( 7 /9) of all the patients achieved e GFR ≥90 ml·min- 1·1. 73 m- 2,and in the ADV group,23. 81%( 10 /42) of all the patients achieved e GFR < 90 ml·min- 1·1.73 m- 2. Conclusion During the treatment,LDT can increase e GFR and improve renal function significantly,while ADV may reduce e GFR,with potential nephrotoxicity. During the treatment for patients with CHB,e GFR may reflect renal injury much earlier than Scr. The mechanisms of action of LDT in increasing e GFR and protecting renal function await further investigation.

     

    • FullText(HTML)
    • References(16)
  • [1] LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
    [2]DUARTE-ROJO A,HEATHCOTE EJ.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B[J].Therap Adv Gastroenterol,2010,3(2):107-119.
    [3]WANG GS,CAI HD.Adefovir dipivoxil and tenofovir-associated tubulopathy[J].ADRJ,2010,12(1):31-36.(in Chinese)王桂爽,蔡皓东.阿德福韦酯和替诺福韦相关性肾小管病[J].药物不良反应杂志,2010,12(1):31-36.
    [4]COCA SG,YALAVARTHY R,CONCATO J,et al.Biomarkers for the diagnosis and risk stratification of acute kidney injury:a systematic review[J].Kidney Int,2008,73(9):1008-1016.
    [5]CASTRO AF,CORESH J.CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey(NHANES)[J].Am J Kidney Dis,2009,53(3 Suppl3):s46-s55.
    [6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):I-XVI.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):I-XVI.
    [7]QI X,WANG JY,MAO RC,et al.Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China[J].J Viral Hepat,2015,22(1):46-54.
    [8]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146.
    [9]MARCELLIN P,HEATHCOTE EJ,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.
    [10]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(Suppl 5):s185-s195.
    [11]XUN L,CHENG W,HUA T,et al.Assessing glomerular filtration rate(GFR)in elderly Chinese patients with chronic kidney disease(CKD):a comparison of various predictive equations[J].Arch Gerontol Geriatr,2010,51(1):13-20.
    [12]LIAW YF,GANE E,LEUNG N,et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.
    [13]TANAKA M,SUZUKI F,SEKO Y,et al.Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J].J Gastroenterology,2014,49(3):470-480.
    [14]NA Y,LOU XZ.Influence of telbivudine and adefovir monotherapy on renal function in patients with chronicH epatitis B[J].J China Med Univ,2014,43(5):446-448.(in Chinese)那妍,娄宪芝.替比夫定与阿德福韦酯治疗对慢性乙型肝炎患者肾脏功能影响的比较[J].中国医科大学学报,2014,43(5):446-448.
    [15]LI XX,ZHONG CX,YANG SL,et al.Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B[J].J South Med Univ,2012,32(6):826-829.(in Chinese)李小溪,钟春秀,杨淑玲,等.阿德福韦酯和替比夫定单药治疗慢性乙型肝炎对肾脏功能影响的比较[J].南方医科大学报,2012,32(6):826-829.
    [16]LEE M,OH S,LEE HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J].J Viral Hepat,2014,21(12):873-881.
    • Relative Articles

  • Relative Articles

    [1]Liang ZHANG, Hao LI, Shanhong TANG. Thoughts on the diagnosis and treatment of hepatic encephalopathy associated with blood ammonia in liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2942-2945. doi: 10.3969/j.issn.1001-5256.2023.12.028
    [2]Yijing ZHU, Wei LI, Shousong ZHAO. Research advances in the association between sarcopenia and hepatic encephalopathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 671-676. doi: 10.3969/j.issn.1001-5256.2023.03.030
    [3]Humin ZHU, Xudong LIU, Lu HUANG, Pinhua LI, Tiexiong WU, Huazhen PANG. Expression levels of gastrointestinal hormones in the progression of liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2364-2368. doi: 10.3969/j.issn.1001-5256.2021.10.021
    [4]Cheng Na, Yang Jing. Association of estrogen receptor α gene polymorphisms with hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 186-189. doi: 10.3969/j.issn.1001-5256.2020.01.044
    [5]Tang ShiHao, Chen Hui, Han GuoHong. Association between gut microbiota and hepatic encephalopathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1109-1113. doi: 10.3969/j.issn.1001-5256.2019.05.041
    [6]Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2076-2089. doi: 10.3969/j.issn.1001-5256.2018.10.007
    [7]Wang JiuHeng, Li GuiYu, Wang YunZhong, Xu ChengJun, Zhao TieJian. A case of young female with cryptogenic cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(5): 948-949. doi: 10.3969/j.issn.1001-5256.2016.05.031
    [8]Wang MaoRong. Paying attention to nutritional management of hepatic encephalopathy in patients with liver cirrhosis:  introduction to ISHEN consensus[J]. Journal of Clinical Hepatology, 2013, 29(9): 649-651. doi: 10.3969/j.issn.1001-5256.2013.09.004
    [9]Mou XiaoHui. Management of spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1015-1018.
    [10]Duan WeiJia, You Hong. Therapy advances in primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(6): 581-583.
    [11]Hu YuLin, Quan XiangLan. Research state and prospect of hyponatremia in cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 330-332.
    [12]Xu ZhengJie, Zhong Yan, Liu Jiao, Fan JianGao.

    Analysis of characteristics of 58 cases of cryptic cirrhosis in Shanghai area

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 264-266.
    [13]Wang Yu, Po YunFeng, Xu XianJi. A retrospective analysis of 74 patients with hipatic encephalopathy[J]. Journal of Clinical Hepatology, 2005, 21(3): 166-167.
    [15]Xiang HaiPing, Jin RongHua, Guo XinHui, Chen YiSen, Gao JiRong, Jiang TaiYi. The GH resistance of liver cirrhosis improved by rGH therapy.[J]. Journal of Clinical Hepatology, 2004, 20(2): 93-95.
    [17]Mao JunLing, Chen YuBo, Xia DongMing, Zhang YanHua. Clinical significance of serumthyroxine determination in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2001, 17(2): 101-102.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(5)

    1. 张效收，李红专，李晶，史恒蔚，李彦强，张永健，刘跃振，赵建栋. 基于“肝藏血主疏泄”理论探讨肝及肝脏疾病与绝经后骨质疏松的关系. 现代中医药. 2024(01): 32-36 .
    2. 何秋霞，纪汉斌，禹文海，魏大巧，黄芬. 雌、孕激素与病毒感染的关系. 中国人兽共患病学报. 2019(03): 258-262+270 .
    3. 王建红，任毅，尹建红，杨静. 高泌乳素血症临床诊断新进展. 中国实用神经疾病杂志. 2018(02): 230-232 .
    4. 李秀兰，刘青，王夫川，王明，马晓鹏. 诺舒阻抗控制子宫内膜去除术治疗肝病患者异常子宫出血的远期疗效. 肝脏. 2018(07): 596-599 .
    5. 李秀兰，刘青，冉冉，张华. 473例肝病患者异常子宫出血的病因分析. 北京医学. 2017(09): 924-927 .

    Other cited types(2)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 8.3 %FULLTEXT: 8.3 %META: 89.3 %META: 89.3 %PDF: 2.3 %PDF: 2.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.6 %其他: 4.6 %其他: 0.1 %其他: 0.1 %Canada: 0.1 %Canada: 0.1 %India: 0.3 %India: 0.3 %Taiwan, China: 0.1 %Taiwan, China: 0.1 %United States: 0.3 %United States: 0.3 %三亚: 0.1 %三亚: 0.1 %上海: 3.1 %上海: 3.1 %丽水: 0.4 %丽水: 0.4 %北京: 11.9 %北京: 11.9 %南宁: 0.1 %南宁: 0.1 %厦门: 0.1 %厦门: 0.1 %台州: 0.5 %台州: 0.5 %合肥: 0.1 %合肥: 0.1 %吉林: 0.5 %吉林: 0.5 %哈尔滨: 0.1 %哈尔滨: 0.1 %哥伦布: 0.1 %哥伦布: 0.1 %坦佩: 0.1 %坦佩: 0.1 %天津: 0.1 %天津: 0.1 %张家口: 2.5 %张家口: 2.5 %新德里: 0.3 %新德里: 0.3 %无锡: 0.3 %无锡: 0.3 %昆明: 0.3 %昆明: 0.3 %杭州: 0.7 %杭州: 0.7 %榆林: 0.3 %榆林: 0.3 %武汉: 0.3 %武汉: 0.3 %池州: 0.1 %池州: 0.1 %海得拉巴: 0.1 %海得拉巴: 0.1 %淄博: 0.1 %淄博: 0.1 %湖州: 0.5 %湖州: 0.5 %罗奥尔凯埃: 0.1 %罗奥尔凯埃: 0.1 %芒廷维尤: 38.0 %芒廷维尤: 38.0 %莫斯科: 0.8 %莫斯科: 0.8 %衢州: 0.3 %衢州: 0.3 %西宁: 28.1 %西宁: 28.1 %贵阳: 0.1 %贵阳: 0.1 %迈阿密: 0.1 %迈阿密: 0.1 %都柏林: 0.1 %都柏林: 0.1 %重庆: 1.8 %重庆: 1.8 %金华: 0.1 %金华: 0.1 %银川: 0.1 %银川: 0.1 %长春: 0.3 %长春: 0.3 %长沙: 0.5 %长沙: 0.5 %长治: 0.3 %长治: 0.3 %驻马店: 0.1 %驻马店: 0.1 %黄南: 0.1 %黄南: 0.1 %黑尔福德: 0.1 %黑尔福德: 0.1 %其他其他CanadaIndiaTaiwan, ChinaUnited States三亚上海丽水北京南宁厦门台州合肥吉林哈尔滨哥伦布坦佩天津张家口新德里无锡昆明杭州榆林武汉池州海得拉巴淄博湖州罗奥尔凯埃芒廷维尤莫斯科衢州西宁贵阳迈阿密都柏林重庆金华银川长春长沙长治驻马店黄南黑尔福德

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (475) PDF downloads(108) Cited by(7)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[306]TodayPV[733]Online[51]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return